Peptide Based Cancer Therapeutics Market Size, Share, Trends & Forecast, 2026–2034

What is Peptide Based Cancer Therapeutics?

Peptide-based cancer therapeutics are drugs, which are comprised of short amino-acid chains, usually 2-50 residues long, and are made to affect cancerous receptors, pathways, antigens, or cells. They include hormonal peptides, anticancer peptides, peptide vaccines, peptide-drug conjugates (PDCs), and peptide receptor radionuclide therapy (PRRT), and are designed to provide improved targeting and reduce the side effects typical for chemotherapeutic agents.

Peptide either inhibits the receptor or delivers a cytotoxic or radioactive payload or stimulates the immune response. Lutathera (a PRRT) is an example of such a drug, which is used to treat somatostatin receptor-positive neuroendocrine tumors, and the US FDA approved its use in patients 12 years of age and older in April 2024.

How Peptide Based Cancer Therapeutics Works?

The mechanism of action involves identification of tumor-associated molecules, design of a peptide that recognizes and binds them, introduction of the peptide to target the site and deliver a payload or stimulate the immune system to attack the cancer cell. Due to their small size, peptides can penetrate the tissues deep, but their short half-life, susceptibility to enzymatic degradation, and low oral bioavailability limit their use. Cyclization, PEGylation, lipidation, and delivery via nanoparticles can help address these issues, while conjugating to a payload or a radioactive isotope usually makes the treatment more effective and less damaging to healthy cells.

The growing development of peptide-drug conjugates (PDCs) and cancer vaccines is creating new opportunities in the market. PDCs are a type of drug that utilize peptides to link together cancer-fighting drugs. Peptide-based cancer vaccines are designed to stimulate the patient's immune response to fight against cancer cells. There are a number of pharmaceutical companies and research institutes which are exploring the potential of such therapies for various cancer indications. With an increase in candidates entering the market space through the R&D pipeline, each offering different potential treatment options for cancer patients, successful clinical trials and regulatory approvals can drive market growth.

Increasing R&D investment in the field is fueling the development in the peptide-based cancer therapeutics market. The pharmaceutical companies, biotechnology companies, and research institutes conducting research in this space are contributing to the market growth. Improvements made by the companies in peptide synthesis, drug design and manufacturing are enabling the researchers to design and utilize novel peptide-based drugs for therapeutic applications. Researchers are also working on exploring new peptide treatment combinations with other treatment modalities for cancer therapeutics. The rising amount of interest and investment in the field will result in an increase in the number of new drug candidates. These developments will support the market growth in the future through clinical trials and regulatory approvals.

Impact of AI on Market

• AI helps researchers identify promising peptide candidates faster by analyzing large amounts of biological data.
• AI supports the design of peptides with improved stability and cancer-targeting abilities.
• AI helps analyze genomic data to identify patients suitable for personalized peptide-based cancer treatments.
• AI helps researchers select suitable patients for clinical trials by analyzing tumor characteristics.
• AI reduces early-stage research time by identifying promising drug candidates and filtering out less suitable options.
• AI helps researchers identify promising combinations of peptide therapies and other cancer treatments.

Industry Dynamics

Driver: Rising Cancer Cases

The increasing prevalence of cancer across the globe is driving the peptide based cancer therapeutics market growth. According to the World Health Organization, an estimated 35 million cancer cases are anticipated worldwide by the year 2050. The demand for advanced and effective treatment options for cancer is rising significantly. Therapeutics that are based on peptides offer promising targeted treatment and reduce collateral damage to healthy cells. The rising cancer incidence rates, an aging population, and a strong emphasis on improving treatment outcomes are major factors driving the market growth. Peptide-based cancer therapeutics are gaining significant attention from researchers and pharmaceutical companies as they offer the potential to effectively treat cancerous tumor cells while minimizing damage to the surrounding normal cells (Source: who.int).

Driver: Growing Interest in Precision Oncology

The increasing interest in precision oncology is one of the prime factors fueling the growth of the peptide-based cancer therapeutics market. For instance, in October 2026, 10x Genomics collaborated with Fred Hutchinson Cancer Center for development of single cell and spatial technology for cancer diagnostics. Precision oncology makes it possible to choose the most appropriate treatment for a cancer patient on an individual level. It is a very effective method since the therapeutics are specifically designed to target certain proteins that are expressed by tumor cells or to enhance the body’s ability to fight cancer. The rising focus on implementing precision medicine and improved diagnostics in oncology is creating numerous opportunities for the global peptide-based cancer therapeutics market (Source: prnewswire.com).

Restraining Factor and Adoption Challenge : Stability and Short Half-Life

The major challenges of the peptide-based cancer therapeutics market is the stability and short half-life of peptides. Peptides have shown to be unstable and prone to degradation in different environments through enzyme activity and other biological mechanisms. This characteristic significantly impacts their biological half-life and decreases their efficiency in treating certain diseases. Moreover, this challenge often requires peptides to be delivered by special methods to ensure targeted inhibition and cure. In addition, increasing the stability of peptides may lead to significant expenditures on research and development.

Restraining Factor and Adoption Challenge : High Manufacturing Costs

The high manufacturing costs of peptide drugs limits the industry growth. The production process involves advanced biotechnological equipment, various technologies, and extensive research. In addition, multiple stages of production need to be thoroughly controlled and tested to ensure a drug’s quality and safety profile. The complex structure of a peptide molecule may increase the cost of production. Furthermore, the costs of manufacturing may impact the final price of a drug, which, in turn, can limit patient access and overall adoption of therapies.

Opportunity : Combination Immunotherapy

Combination therapies involving peptide-based cancer therapeutics and immunotherapy present a lucrative opportunity in the market. Such combination therapies have the potential to elicit better immune response against cancer and lead to improved clinical outcomes for patients. Pharmaceutical companies are witnessing a growing interest in combination treatment regimens due to rising clinical evidence supporting their potential benefits. Therapeutically successful clinical trials may drive the overall demand for peptide-based therapeutics in the market.

Opportunity : Theranostics

Incorporating theranostics presents a significant opportunity for peptide-based cancer therapeutics in the future. Theranostics involves diagnosis and simultaneous treatment of disease, which can be possible through peptides that can selectively recognize cancerous cells and bind to specific receptors. The opportunity in this area will be driven by the need for effective personalized patient-specific treatment and a growing interest for targeted therapy. Peptide-based cancer therapeutics have the potential to offer novel treatment avenues and applications in theranostics.

Opportunity : Biomarker Led Enrollment

The biomarker led enrollment is expected to drive the growth of peptide-based cancer therapeutics. Biomarker enrollment helps to determine the most appropriate therapies for treating individual patients based on specific molecular markers. The approach would help to identify suitable candidates for peptide-based drugs during clinical trials, which would accelerate the processes of development and commercialization. Biomarker led enrollment will be driven by the use of biomarker testing and personalized medicine in patient treatment. Success in this arena will offer immense growth opportunities for the peptide-based cancer therapeutics market.

Types of Peptide-Based Cancer Therapies

Peptide-based cancer therapy modalities

Modality	How it works	Illustrative examples	Stage	Typical cancers
Hormonal peptides	Suppress hormone signaling (LHRH agonists and antagonists) or hormone secretion (somatostatin analogs)	Goserelin (Zoladex), leuprolide (Lupron, Eligard), degarelix (Firmagon), octreotide, lanreotide	Marketed	Prostate, breast, neuroendocrine
Anticancer peptides	Disrupt tumor cell membranes or trigger apoptosis; modulate immune signaling	LTX-315 and ST101 (Phase 2 programs)	Clinical	Solid tumors
Peptide cancer vaccines	Present tumor antigens to train T cells	SurVaxM (glioblastoma, Phase 2); Riavax (approved in South Korea, pancreatic)	Clinical; one regional approval	Glioblastoma, pancreatic, melanoma
Personalized neoantigen vaccines	Sequence the tumor, select patient-specific neoantigens, synthesize peptides	Personalized multipeptide vaccine trials (NCI-listed)	Clinical	Melanoma, breast, lung, bladder, gastroesophageal
Peptide-drug conjugates	Tumor-targeting peptide + linker + cytotoxic payload	Zelenectide pevedotin (Bicycle, Phase 2/3); TH1902 (Phase 1)	Clinical	Bladder/urothelial, breast, lung
PRRT	Receptor-binding peptide carrying a radionuclide	Lutathera (lutetium Lu 177 dotatate)	Marketed	SSTR-positive GEP-NETs
Tumor-homing / cell-penetrating peptides	Recognize tumor markers or cross the membrane to carry payloads	RGD peptides (tumor vasculature targeting)	Preclinical to clinical	Solid tumors

Source: Polaris Market Research Analysis

Representative marketed peptide-based cancer drugs

Class	Products	Indication focus
LHRH agonists and antagonists	Zoladex (goserelin), Lupron and Eligard (leuprolide), Camcevi (leuprolide), Trelstar (triptorelin), Decapeptyl, Firmagon and Gonax (degarelix)	Prostate cancer; goserelin also breast cancer
Somatostatin analogs	Sandostatin and Bynfezia (octreotide), Somatuline Depot (lanreotide)	Neuroendocrine tumors, carcinoid syndrome
Peptide receptor radionuclide and imaging	Lutathera (Lu 177 dotatate), Netspot (Ga 68 dotatate)	SSTR-positive GEP-NETs (therapy and PET imaging)
Proteasome inhibitors (peptide-derived)	Velcade (bortezomib), Kyprolis (carfilzomib), Ninlaro (ixazomib)	Multiple myeloma, mantle cell lymphoma
Other peptide or peptide-like oncology drugs	Istodax (romidepsin), Cosmegen (dactinomycin), Mepact (mifamurtide)	T-cell lymphoma, sarcomas, osteosarcoma (region-specific)

Source: Polaris Market Research Analysis

Peptide-Drug Conjugates Are Expanding Targeted Cancer Therapy

Peptide-drug conjugates (PDCs) can be used to improve targeted delivery of anti-cancer therapeutics by providing a means of directing the drug toward specific tumour targets. Peptides can be used as targeting moieties to increase the targeting specificity and decrease toxicity. An increased focus on developing targeted therapeutics and the progress in drug discovery and delivery could drive the peptide therapeutics market.

Peptide-drug conjugates vs. antibody-drug conjugates

Attribute	Peptide-drug conjugate (PDC)	Antibody-drug conjugate (ADC)
Targeting molecule	Peptide	Monoclonal antibody
Molecular size	Smaller	Larger
Tumor penetration	Generally higher	More limited
Circulation time	Usually shorter	Usually longer
Manufacturing	Relatively simpler	More complex
Payload delivery	Targeted	Targeted
Clinical maturity	Few approved; Lutathera is the established radioligand example; many in trials	More than 20 approved cancer ADCs and 800+ in trials (R&M, 2025)

Source: Polaris Market Research Analysis

Personalized Neoantigen Peptide Vaccines Are Advancing Precision Oncology

Personalized neoantigen peptide-based vaccines provide a platform for the development of individualized therapeutic and preventive vaccines based on the unique mutations of tumours. Therapeutic vaccines are aimed at treating the disease, while preventive vaccines are designed to avoid the disease from appearing. Peptide-based vaccines have benefited from the rising interest in personalized cancer therapeutics. The overall growing interest in personalized medicine provides a strong impetus to research and development of such vaccines for selected indications.

Peptide Cancer Vaccines Are Expanding Combination Immunotherapy

Peptide cancer vaccines are being explored as an effective component in combination immunotherapy due to their ability to prime the immune system against multiple cancer-specific targets. Such vaccines are able to provide additional therapeutic benefit to cancer patients through the combination with various checkpoint inhibitors. Combination immunotherapy is attracting considerable interest for treating diverse indications, while enhanced knowledge of the mechanisms driving cancer development supports the ability of peptide-based vaccination to provide effective treatment with manageable side-effects. These factors, along with the rising focus on immunotherapy and the progress in clinical research, are likely to promote the introduction of novel peptide-based cancer vaccines.

Peptide Receptor Radionuclide Therapy Is Expanding Targeted Oncology

Peptide receptor radionuclide therapy (PRRT) is based on the use of peptides bearing a radionuclide attached to a bifunctional chelator. This allows targeting of tumours possessing specific cell surface receptors followed by delivery of a cytotoxic radiation dose. Despite being currently limited to the treatment of neuroendocrine tumors, PRRT has drawn significant focus and is expected to see further development in the future. Interest in PRRT, as well as advancements in patient stratification, biomarker discovery and radiopharmaceutical design, will contribute to the expansion of the application of peptide-based therapeutics.

Hormonal Peptide Therapies: Goserelin, Leuprorelin, Degarelix and Somatostatin Analogs

Hormonal cancer therapies using peptide agonists and antagonists are an important class of therapeutics targeting the hormonal pathways responsible for tumor growth. Hormonal peptides such as gonadotropin releasing hormone agonists and antagonists, including goserelin, leuprorelin and degarelix, regulate the production of testosterone and thus inhibit the growth of androgen-sensitive prostate cancers. Similarly, somatostatin analogs octreotide and lanreotide can be used in the treatment of certain neuroendocrine tumors. Thus, such therapeutics are valuable and well-established treatments for some cancers. The continuous demand for hormonal cancer treatments and the enhanced quality of peptide drug design contribute to the growth of the market segment.

Tumor-Homing and Cell-Penetrating Peptides Are Improving Targeted Delivery

Tumor-homing and cell-penetrating peptides are investigated for their ability to enhance targeted drug delivery and overcome the limitations of current anti-cancer treatments. These are particularly useful for the creation of tumour-specific therapeutics. Both types of peptides possess unique properties allowing them to home to specific cells or penetrate cell membranes, potentially enabling targeted drug delivery and reducing side effects related to healthy tissue damage. Research into targeted delivery mechanisms is rising, which drives the search for novel approaches. The peptide-based delivery system is likely to see substantial development, improving the treatment of diverse medical conditions.

Anticancer Peptides: Apoptosis-Inducing and Immune-Modulating Approaches

Anticancer peptides are investigated for their potential to induce apoptosis of cancer cells or trigger an immune response against them. Peptides can be engineered to utilise various mechanisms to kill tumour cells. They are considered important for the development of new cancer treatment modalities. Enhanced understanding of the properties of cancer cells and the biological activity of diverse peptides contribute to the rising interest in the field. However, the safety and efficacy of most approaches still need to be verified.

Report Segmentation

By Cancer Type Analysis

The lung cancer is expected to witness growth of CAGR 10.7% during the forecast period as the rising prevalence of lung cancer is propelling the peptide therapeutics market. The increasing need for targeted therapies and immunotherapies is fueling the development of peptide vaccines and conjugates. This, in turn, is anticipated to enhance the precision in targeting cancer cells and thus lead to improved treatment outcomes.

The breast cancer is expected to witness growth of CAGR 10.5% during the forecast period as peptide therapeutics is witnessing a surge in demand for the treatment of breast cancer. The growing inclination toward personalized medicine, peptide vaccines, and combination immunotherapies is creating new opportunities for the market. Besides, the expansion of therapeutic options for treating specific tumor types is also projected to augment the segment growth during the forecast period.

The prostate cancer dominated with largest share of 18.6% in 2025 as the high unmet need for effective treatment against prostate cancer is supporting the peptide therapeutics market. Notably, the existing hormone therapies such as goserelin and leuprorelin are playing a major role in the treatment of prostate cancer, which, in turn, drives the segment. Moreover, the rising research activities in targeted drug delivery and development of peptide-based therapeutics are also complementing the growth of this segment.

The colorectal cancer is expected to witness growth of CAGR 10.3% during the forecast period. The rising incidence of colorectal cancer is anticipated to drive the development of novel treatment options for the disease. The growing research activities in relation to peptide vaccines, targeted drug delivery, and combination immunotherapies are expected to boost the peptide therapeutics market for treating colorectal cancer. Additionally, the advancements in relation to cancer biomarker discovery are also projected to augment the segment growth.

The melanoma segment is expected to witness growth of CAGR 11.2% during the forecast period. The rising need for cancer immunotherapies is fueling the development of peptide therapeutics for melanoma. The development of peptide vaccines enables the activation of the immune system against specific tumor-associated antigens expressed on cancer cells. Moreover, the increasing research activities in relation to personalized cancer vaccines and combination treatment modalities are also supporting the segment growth.

The stomach is expected to witness growth of CAGR 9.8% during the forecast period. The high prevalence of stomach cancer and the need for improved treatment options are driving the development of peptide therapeutics. The growing research activities in relation to targeted drug delivery and treatment with therapeutic peptide vaccines is complementing the segment growth. Additionally, advancements in relation to tumor biomarker discovery could also create new opportunities for the development of personalized treatment options.

The neuroendocrine tumor segment is expected to witness growth of CAGR 11.5% during the forecast period. The increased utilization of somatostatin analogs and peptide receptor radionuclide therapy is supporting the peptide therapeutics segment for treating neuroendocrine tumors. This is attributable to the presence of specific somatostatin receptors on tumor cells that can be targeted by these therapies. Moreover, the growing inclination toward targeted therapy and advancements in receptor imaging are also projected to drive the segment growth.

The pancreatic cancer is expected to witness growth of CAGR 11.7% during the forecast period as the rising incidence of pancreatic cancer is creating immense pressure on the healthcare sector to develop novel treatment modalities. The research activities in relation to development of targeted therapies, cancer vaccines, and immunotherapies are rising, which, in turn, is anticipated to propel the peptide therapeutics market for treating pancreatic cancer. Additionally, the advancements in tumor research are also supporting the development of novel therapeutics for targeting cancer cells.

The hematological segment is expected to witness growth of CAGR 10.1% during the forecast period. The increasing research activities in relation to various blood cancers such as leukemia and lymphoma are creating new opportunities for peptide therapeutics. The development of peptide vaccines could help in enabling the immune system to specifically target tumor-associated antigens expressed on cancerous cells. Moreover, the growing need for targeted treatment and combination therapies is also projected to augment the segment growth.

The CNS segment is expected to witness growth of CAGR 9.6% during the forecast period. The rising prevalence of primary brain tumors is creating the need for advanced treatment options such as peptide therapeutics. Certain peptides could facilitate targeted drug delivery to the tumor cells. Additionally, the increased research activities in relation to blood-brain barrier disruption and advancement in drug delivery technologies are also projected to drive the segment growth.

By Mode of Mechanism Analysis

Receptor-Targeting Peptides dominated the peptide based cancer therapeutics market share with 32.8% as growing demand for targeted cancer treatments is driving receptor-targeting peptides. These peptides bind to specific receptors on cancer cells, helping deliver therapeutic agents to the intended site. Advances in cancer research and improved identification of tumor receptors are supporting the development of more precise peptide-based therapies.

Apoptosis-Inducing Peptides is expected to witness growth of CAGR 11.3% during the forecast period as increasing interest in treatments that promote cancer cell death is driving this segment. Apoptosis-inducing peptides activate the natural process of programmed cell death in cancer cells. Growing research into targeted therapies and combination treatments is encouraging the development of these peptides for different cancer types.

Immune-Modulating Peptides is expected to witness growth of CAGR 11.6% during the forecast period due to growing adoption of immunotherapy for immune-modulating peptides. These peptides can influence immune responses and help the body recognize or attack cancer cells. Increasing research into peptide cancer vaccines, personalized medicine, and combination immunotherapy is creating opportunities for further development.

Angiogenesis-Inhibiting Peptides is expected to witness growth of CAGR 9.9% during the forecast period as the need to limit tumor growth is driving research into angiogenesis-inhibiting peptides. These peptides aim to block the formation of new blood vessels that supply tumors with oxygen and nutrients. Growing interest in targeted cancer treatments is encouraging researchers to explore their potential across different cancer types.

Cell-Penetrating Peptides is expected to witness growth of CAGR 10.8% during the forecast period driven by growing demand for improved drug delivery. These peptides help therapeutic substances cross cell membranes and reach their intended targets. Advances in peptide design and drug delivery technologies are encouraging research into treatments that improve drug access to cancer cells.

Tumor-Homing Peptides is expected to witness growth of CAGR 11.4% during the forecast period due to increasing demand for targeted cancer treatment. These peptides are designed to recognize and accumulate in tumor tissues, helping deliver therapeutic agents more precisely. Growing research into targeted drug delivery, peptide-drug conjugates, and personalized cancer therapies is encouraging development in this segment.

Peptide-Drug Conjugates (PDCs) is expected to witness growth of CAGR 12.1% during the forecast period as growing interest in targeted cancer therapies is driving the development of peptide-drug conjugates (PDCs). These treatments combine peptides with cancer-fighting drugs to improve delivery toward specific cancer cells. Advances in peptide engineering, rising research investment, and the need to reduce damage to healthy tissues are supporting this segment's growth.

By Distribution Channel Analysis

The hospital pharmacies dominated the peptide based cancer therapeutics market size with 54.2% due to the increasing use of peptide-based therapies in the treatment of malignancies in a specialized setting. This segment covers hospitals as the key providers of cancer specialists, sophisticated treatment equipment, and patient-specific supervision. The rising incidence rate of malignancies and the growing need for monitored treatment will drive the segment’s growth.

The Specialty and retail pharmacies is expected to witness growth of CAGR 10.4% during the forecast period driven by the increasing demand for easy access to prescribed cancer therapeutics. It will provide access to selected supportive care medications necessary for the treatment and eligible dosing forms for outpatient programs. The growing number of retail pharmacies and the availability of healthcare services will contribute to the segment’s growth.

The online pharmacies is expected to witness growth of CAGR 12.8% during the forecast period due to the increasing use of online services in the healthcare sector. Online platforms will offer convenience in terms of prescription ordering, home delivery, and medication access. The growing use of the Internet and the demand for easy access to medicines will drive the segment’s growth, if applicable in the particular jurisdiction.

Advances in Peptide Delivery Are Improving Stability and Half-Life

The progress in peptide delivery is overcoming the problems of stability and short half-life. The new forms of delivery and formulation may shield the peptide from being degraded in the body, thus increasing its effectiveness and targeting capacity to cancerous cells. These developments also allow for less frequent dosing, which is more convenient for the patient, and promote the advancement of peptide-based cancer treatments.

AI and Genomic Profiling Are Accelerating Peptide Discovery and Patient Selection

The utilization of AI and genomic profiling is expediting the process of peptide discovery and patient selection. The former can analyze substantial amounts of data in search of potential drugs. The latter can identify genetic anomalies that could be present in the tumor of an affected person. Both are contributing factors to the creation of more targeted treatments and the separation of viable candidates for research, clinical trials, and therapy.

Regional Insights

North America Accounted for the Largest Market Share in 2025

North America dominated the market with 45.7% share in 2025 driven by the high investment in cancer research and the adoption of advance treatment options. The existence of key pharma/bio companies supports the development of peptide-based cancer therapies. Increased healthcare expenditure, established clinical research facilities, and the growing focus on personalized medicine are also factors which contribute to the market growth. In the region, rising government funding and collaboration between research institutes and pharmaceutical companies, which promote the development of peptide-based drugs, cancer vaccines, and targeted therapeutics.

The Asia Pacific peptide-based cancer therapeutics market is expected to witness growth of CAGR 10.6% during the forecast period driven by the rising cancer prevalence, increasing healthcare expenditure, and growing investment in biotech research. In China, there is government support and robust pharma manufacturing which contribute to the market growth. India benefits from its established pharmaceutical industry and Increased access to cancer care, while Japan is supported by the aging population, sophisticated healthcare system and advanced cancer research. South Korea is experiencing market growth due to increased biotech investment, government spending, and collaboration between pharma companies and academic research institutes. According to the Geo Factbook, South Korea spend 9.70% of is GDP in healthcare sector (Source: geofactbook.com).

Europe is expected to witness growth of CAGR 9.8% during the peptide-based cancer therapeutics market forecast period driven by strong biomedical research, the presence of key pharmaceutical companies, and the rising emphasis on personalized cancer treatment. Increased government funding and research collaborations promote the development of peptide-based drugs and cancer vaccines. The region has established clinical research infrastructure which supports the conduct of clinical trials of new therapeutics. Growing interest in the peptide-based targeted treatment and increased investment in biotech are additional factors contributing to the market growth. Moreover, the supportive environment for innovative drug development across Europe promotes the regional market growth.

Latin America is expected to witness growth of CAGR 10.7% during the forecast period driven by the rising cancer burden and the need of improved treatment options. Increasing healthcare infrastructure and access to cancer diagnosis/treatment facilities support the adoption of advanced therapeutics in the region. Growing investment in pharmaceutical research/development, as well as offering healthcare services, creates opportunities for peptide-based cancer therapeutics. Moreover, increased awareness of the market potential and collaboration with international pharma companies might accelerate the market growth across major Latin American countries, including Brazil, Mexico, and others.

The Middle East and Africa is expected to witness growth of CAGR 9.4% during the forecast driven by the rising cancer prevalence and increased healthcare expenditure. Government initiatives to improve cancer diagnosis/treatment promotes the adoption of peptide-based cancer therapeutics across the region. Growing investment in healthcare infrastructure, such as specialized hospitals, oncology centers, and medical research facilities, creates opportunities for peptide-based cancer therapeutics in the region. Additionally, the international pharma company partnerships and government efforts to improve local healthcare capabilities might promote the regional market growth in the future.

Key Market Players & Competitive Insights

The peptide-based cancer therapeutics market is competitive, with major pharmaceutical companies and specialized biotechnology firms focusing on drug development, targeted therapies, and cancer vaccines. Companies such as AstraZeneca, Pfizer, Amgen, Novartis, and Bristol Myers Squibb benefit from strong research capabilities. Meanwhile, Bicycle Therapeutics, PeptiDream, and Sapience Therapeutics focus on innovative peptide technologies. Strategic partnerships, clinical trials, and investment in research are key strategies supporting competition and market expansion.

Vendor positioning

Company	Representative peptide-oncology position	Modality
AstraZeneca PLC	Zoladex (goserelin) implant	Hormonal peptide
Novartis AG	Lutathera; Sandostatin (octreotide)	PRRT; somatostatin analog
Ipsen Pharma	Somatuline Depot (lanreotide)	Somatostatin analog
Takeda Pharmaceutical Company Limited	Ninlaro (ixazomib); Velcade partner; leuprolide in Japan	Proteasome inhibitor; LHRH
Amgen Inc.	Kyprolis (carfilzomib)	Proteasome inhibitor
AbbVie Inc.	Lupron Depot (leuprolide)	LHRH agonist
Bicycle Therapeutics	Zelenectide pevedotin (Phase 2/3)	PDC (bicyclic peptide)
PeptiDream	Peptide Discovery Platform System	Discovery platform
Perspective Therapeutics	Radioligand programs	PRRT / radioligand
Sapience Therapeutics	ST101 (Phase 2)	Anticancer peptide
Bristol-Myers Squibb	Radioligand platform via RayzeBio (2024 acquisition)	PRRT / radioligand

Source: Polaris Market Research Analysis

Some of the Peptide Based Cancer Therapeutics companies include:

• AstraZeneca PLC
• Abbott
• Allergan plc
• Teva Pharmaceuticals
• Pfizer Inc.
• Takeda Pharmaceutical
• Amgen, Inc.
• Johnson & Johnson
• AbbVie Inc.
• Valeant Pharmaceuticals Inc.
• Novartis AG
• Ipsen Pharma
• Bicycle Therapeutics plc
• PeptiDream Inc.
• Sapience Therapeutics, Inc.
• Perspective Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Ferring Pharmaceuticals
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company

Recent Developments

• September 2026, TwoStep Therapeutics raised $62.5m in an oversubscribed Series A round to advance TS-104, its peptide-drug conjugate for solid tumours. The funding followed FDA clearance of the company’s investigational new drug application, enabling a first-in-human Phase I study. (Source: pharmaceutical-technology.com)
• January 2026, Zonsen PepLib Biotech signed a worldwide license agreement with Novartis for an undisclosed peptide-based radioligand therapy asset. Novartis received exclusive global rights and will lead development and commercialization, while PepLib secured a $50 billion upfront payment, potential milestones, and tiered royalties. (Source: finance.yahoo.com)
• November 2025, Ajinomoto Bio-Pharma and Olon partnered to expand peptide manufacturing capacity in Europe. The collaboration aimed to strengthen regional supply resilience and support growing demand for peptide-based therapeutics across pharmaceutical development and commercial production. (Source: europe.peptide-drug-summit.com)

Future Outlook

The peptide-based cancer therapeutics market is expected to grow as demand for targeted and personalized cancer treatments increases. Advances in peptide-drug conjugates, cancer vaccines, and drug delivery technologies may expand treatment options. Rising research investments, clinical trials, and pharmaceutical collaborations are likely to support innovation and create new growth opportunities in the coming years.

Peptide Based Cancer Therapeutics Market Segmentation

By Drug Type Outlook (Revenue – USD Billion, 2021–2034)

• Therapeutic anticancer peptides
• Peptide cancer vaccines
• PDCs
• PRRT
• Cell-penetrating / tumor-homing peptides
• Hormonal peptide therapies
• Other

By Cancer Type Outlook (Revenue – USD Billion, 2021–2034)

• Lung
• Breast
• Prostate
• Colorectal
• Melanoma
• Stomach
• Neuroendocrine
• Pancreatic
• Ovarian
• Hematological
• Brain/CNS
• Biliary tract
• Other solid

By Mode of Mechanism Outlook (Revenue – USD Billion, 2021–2034)

• Receptor-targeting
• Apoptosis-inducing
• Immune-modulating
• Angiogenesis-inhibiting
• Cell-penetrating
• Tumor-homing
• PDCs

By Distribution Channel Outlook (Revenue – USD Billion, 2021–2034)

• Hospital pharmacies
• Specialty and retail pharmacies
• Online pharmacies

By Regional Outlook (Revenue – USD Billion, 2021–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Peptide Based Cancer Therapeutics Market Report Scope

Report Attributes	Details
Market size value in 2025	USD 9.67 billion
Market size value in 2026	USD 10.65 billion
Revenue forecast in 2034	USD 23.13 billion
CAGR	10.2% from 2026 – 2034
Base year	2025
Historical data	2021 – 2024
Forecast period	2026 – 2034
Quantitative units	Revenue in USD billion and CAGR from 2026 to 2034
Segments Covered	By Drug Type, By Cancer Type, By Mode of Mechanism, By Distribution Channel
Regional scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Customization	Report customization as per your requirements with respect to countries, region, and segmentation

Source: Polaris Market Research Analysis